Tianjin grading system improves prognosis prediction in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is notoriously difficult to treat due to its aggressive nature and limited prognostic tools.…
Johns Hopkins study links mild pancreatic duct dilatation to higher cancer risk
Pancreatic ductal adenocarcinoma is projected to become the second-leading cause of cancer death in the United States by…
Novel treatment disrupts tumor immunosuppression in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a five-year survival rate below 10%. University…